Abstract
Dementia mainly includes Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VaD). In addition to cognitive impairment, patients often suffer from behavioral and psychological symptoms of dementia (BPSD). Melatonin administration has emerged as a promising therapeutic strategy with potential benefits for BPSD. This review focuses on the therapeutic effects of melatonin on the core symptoms of dementia and BPSD. Specifically, the impact of melatonin on memory impairment, sleep disturbances, anxiety, depression, delusions, and hallucinations is reviewed. The melatonin’s role in amyloid-β, synuclein aggregation, reactive oxygen species, and dementia subtypes are discussed. We aim to provide an up-to-date review of the emerging application of melatonin; thus, dementia patient care and social welfare can be improved by the appropriate usage of this medication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
